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Background/aim: Alpha-methylacyl-CoA racemase (AMACR), an intracellular enzyme involved in lipid metabolism, has emerged
as an immunohistochemical marker for many types of cancer. Recent studies about the role of lipid metabolism in pathogenesis of
mesothelioma have brought up some positive results. This study was conducted to investigate AMACR expression in the diagnosis of
malignant pleural mesothelioma (MPM) and the correlation of this marker with clinical characteristics and survival.
Materials and methods: The clinicopathologic characteristics and resection materials of 71 patients were reviewed retrospectively.
AMACR expression was evaluated immunohistochemically. The correlations among AMACR expression, clinicopathologic factors, and
survival were investigated.
Results: AMACR expression was detected in 42.3% of the study group. The specificity and sensitivity of AMACR immunostaining in
detecting mesothelioma were 41.1% and 42.3%, respectively. AMACR-positive and negative groups were similar for age, sex, smoking
history, tumor diameter, lymph node involvement, differentiation, T–N factor, and stage. Overall survival was not significantly different
between the groups, either.
Conclusion: The sensitivity of immunostaining was not high enough to use AMACR as a diagnostic tool in MPM. AMACR expression
did not have a prognostic value in MPM, either.
Key words: AMACR, carcinogenesis, mesothelioma

1. Introduction
The most common primary malignant tumor of the
pleura is malignant mesothelioma (MPM). It has four
major histological subtypes: epithelioid, sarcomatoid,
desmoplastic, and biphasic (1).
Mesothelioma appears to have a complex etiology in
which environmental carcinogens (asbestos and erionite),
ionizing radiation, dietary factors, viruses, and genetic
factors act alone or in concert to cause malignancy (2,3).
Current studies showed that lipid metabolism may have an
important role in pathogenesis suggesting new targets for
treatment of MPM (4–6).
Alpha-methylacyl-CoA racemase (AMACR) is an
intracellular enzyme that is involved in the beta-oxidation
of branched fatty acids (7,8). There is increasing evidence
showing that AMACR is a useful marker for many
cancers of the prostate, liver, kidney, and colon (9–11).
However, the expression and clinical effects of AMACR
* Correspondence: drsezgisahin@gmail.com

in mesothelioma have not been researched yet. This study
investigated AMACR expression and its correlation with
clinical characteristics and survival of patients with MPM.
2. Materials and methods
2.1. Patients
The clinicopathologic characteristics of 71 patients who
underwent a surgical resection for therapeutic and/or
diagnostic approaches between June 2000 and June 2009
in our institute were reviewed retrospectively. In the
preoperative evaluation, the results of a biochemistry
panel including renal and liver function tests, alkaline
phosphatase and serum calcium levels, complete blood
count, posteroanterior chest radiographs, computed
tomographic scans of the thorax including the upper
abdomen, and bronchoscopy were obtained for all
of the patients. The relationships between AMACR
immunoreactivity and clinicopathologic factors, including
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age, sex, smoking history, histological type of tumor,
pathologic T–N status, and stage were evaluated.
For correlating pathological findings with survival,
patients who died due to postoperative mortality (1
patient) and patients whose date of death was unknown
(17 patients) were all excluded. The remaining group
comprised 53 patients.
The stage of each patient was evaluated according to
the staging system of the International Mesothelioma
Interest Group (IMIG), revised in 1995 (12).
2.2. Surgical procedure and treatment modality
The surgical procedures consisted of 36 video-assisted
thoracic surgeries (VATS) (50.7%), 14 decortications
(19.7%), 5 pleuropneumonectomies (7%), and 16
chest wall/pleural biopsies (22.5%). VATS and biopsies
were performed for diagnostic approaches, whereas
decortications and pleuropneumonectomies were for
therapeutic approaches. The patient’s performance status,
stage of the disease, and the patient’s own choices were
considered in the choice of treatment modality. Treatment
modalities applied to this group of patients were local
radiotherapy (4 patients, 5.7%), chemotherapy with
cisplatin and gemcitabine or pemetrexed (7 patients, 10%),
local radiotherapy and chemotherapy (6 patients, 8.6%),
pleuropneumonectomy (5 patients, 7.1%), decortication
(7 patients, 10%), and decortication and radiotherapy
and/or chemotherapy (6 patients, 8.6%). After diagnostic
procedures, 35 patients (50%) did not receive any of these
treatments due to their poor performance status or refusal
of treatment.
2.3. Pathologic evaluation
All specimens were histologically reviewed by one pathologist
and the most representative slides of tumors were selected.
Immunohistochemistry was carried out on 5-µm-thick paraffin
sections. Sections were dewaxed in a xylene substitute (Thermo
Scientific, USA) and hydrated with a graded series of ethanol
concentrations and water. Subsequently, antigen retrieval was
obtained by boiling in 0.01 mol/L citrate buffer (pH 6.0) for
20 min in a microwave oven. Sections were incubated with
primary antibody solution for rabbit monoclonal AMACR/

A1

A2

p504S (clone 13H4, Thermo Scientific) at a dilution of 1:100
for 30 min at room temperature. Immunostaining was
performed with a streptavidin–biotin complex kit (Thermo
Scientific). Diaminobenzidine was used as a chromogen. After
incubation, chromogen specimens were counterstained with
Harris hematoxylin and cover-slipped. Samples of prostate
carcinoma were used as a positive control. Negative controls
omitting the primary antibodies were also included.
The intensity of AMACR immunostaining was evaluated by
light microscopy (Labophot 2; Nikon, Japan). Only cytoplasmic
staining was considered. Intensity of staining was graded as 1+
weak, 2+ moderate, 3+ strong. Tumors without any staining
were considered AMACR-negative (13) (Figure 1).
2.4. Statistical analyses
Pearson’s chi-squared test, Yates’ chi-squared test, or Fisher’s
exact test were used to compare differences among groups for
categorical variables. The survival curves were estimated using
the Kaplan–Meier method. Patient survival was expressed by
using time zero as the date of pathologic diagnosis and death
as the end point. The log-rank test was used for comparison of
the survival curves in univariate analysis. In all the statistical
analyses, P < 0.05 was considered statistically significant. All
statistical analyses were performed by SPSS for Windows,
version 15.0.
3. Results
The clinical and pathological characteristics of the patients
are summarized in Table 1. Positive staining was detected
in 42.3% of the cases. The expression of AMACR according
to histological subtypes is expressed in Table 2.
Forty-two percent of 50 patients with epithelioid
mesothelioma and 52.9% of 17 patients with biphasic
mesothelioma were positive for AMACR immunostaining.
Epitheloid sections were found to be AMACR-positive in
four patients with biphasic mesothelioma; in five patients,
only sarcomatoid sections showed positive staining. The
remaining 9 patients with biphasic mesothelioma were
totally AMACR-negative. However, the patients with pure
sarcomatoid (2 cases) and desmoplastic mesothelioma (2
cases) were AMACR-negative.

A3

Figure 1. Samples of slides with MPM showing cytoplasmic AMACR immunostaining with weak (A1), moderate (A2), and
strong (A3) intensity (AMACRX200. H&E).
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Table 1. Patient characteristics.
n = 71
n
Age (years)

%

56.17 ± 11.39

<60 (median)

40

56.30

≥60

31

43.70

Female

26

36.60

Male

45

63.40

Ever smoked

35

49.3

Nonsmokers

36

50.7

Median package/year smoking

22 (10–100)

Sex

History of smoking

T factor
T1
T1a

3

4.2

T1b

0

0

T2

39

54.9

T3

17

23.9

T4

12

16.9

N0

63

88.7

N2

7

9.9

N3

1

1.4

I

2

2.80

II

35

49.30

III

19

26.80

IV

15

21.10

Epithelioid

50

70.40

Sarcomatoid

2

2.80

Biphasic

17

23.90

Desmoplastic

2

2.8

VATS

36

50.7

Decortication

14

19.70

Pleuropneumonectomy

5

7.00

Chest wall/pleural biopsy

16

22.50

N factor

Stage

Histological subtypes

Type of operation

VATS: Video-assisted thoracic surgery.

609

DUYAR et al. / Turk J Med Sci
Table 2. AMACR immunoreactivity according to histological subtypes.
AMACR

Positive staining

Intensity of staining

n

%

0 (%)

1+ (%)

2+ (%)

3+ (%)

30

42.3

41 (57.7)

14 (19.7)

8 (11.3)

8 (11.3)

Epitheloid

29 (58.0)

9 (18.0)

6 (12.0)

6 (12.0)

Sarcomatoid

2 (100.0)

Biphasic

8 (47.1)

5(29.4)

2(11.8)

2(11.8)

Desmoplastic

2 (100.0)

MPM

AMACR: Alpha-methylacyl-CoA racemase, MPM: malignant pleural mesothelioma.

As shown in Table 3, AMACR expression and
clinicopathologic factors, including age, sex, smoking
history, pathologic T–N status, and stage, did not show a
statistically significant correlation (P > 0.05).
In a previous study of our clinic we had explored
AMACR immunoreactivity in adenocarcinoma and
squamous cell carcinoma of the lung (14). When
we compared our results with the results of the
adenocarcinoma group (73 cases) in the previous study,
we found that AMACR immunoreactivity was observed
more frequently in adenocarcinoma group than in the
MPM group (P = 0.046). The specificity and sensitivity of
AMACR immunostaining in detecting MPM were 42.3%
and 41.1%, respectively.
After the patients were excluded according to the
criteria mentioned above, data from remaining 53 patients
were evaluated for survival analysis. The median survival
for the AMACR-negative group was 13 ± 3.65 months
whereas it was 16 ± 5.96 months for the AMACR-positive
group. Although survival lines on the graph seem to be
parallel, we could not show a statistically significant effect
of AMACR on survival (P = 0.190, log-rank). In a larger
group of patients the results may be statistically significant.
We performed Cox regression analysis to reveal the
effect of age, sex, history of smoking, N status, stage,
therapy modality, histological subtype, and AMACR
immunoreactivity on overall survival (Table 4).
N status was proven to have a statistically significant
effect on overall survival of patients with MPM (P = 0.001).
However, we could not show prognostic value of the other
variables (P > 0.05).
4. Discussion
MPM is an important threat to public health, especially
in regions with environmental exposure to asbestos.
The pathologic differential diagnosis of MPM
depends on electron microscopic, histochemical, and
immunohistochemical studies. However, none of these
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methods are 100% specific (1). Therefore, new methods,
especially new immunohistochemical markers, for
diagnosis and prognostic estimation are of interest for
medical research.
AMACR is an intracellular enzyme that is bimodally
distributed to both the peroxisome and the mitochondrion.
It has an important role in the beta-oxidation of branched
fatty acids, bile acid intermediates, and metabolism of
ibuprofen (7,8).
This enzyme takes a part in beta-oxidation of phytanic
acid and pristanic acid. These branched chain fatty
acids are naturally occurring ligands for the nuclear
receptor peroxisome proliferator-activated receptor alpha
(PPAR-α). PPAR-α is one of the nuclear receptor proteins
that has an important role in cellular differentiation,
evolution, and metabolism (8). The enhancement of
PPAR-γ activity with its ligands, and the suppression of
PPAR-α with its inhibitors, may prevent the formation of
lung tumors, as well as accelerate lung cancer therapy (9).
Therefore, it is hypothesized that AMACR, which plays
a role in the metabolism of the ligands of these nuclear
receptors, may affect the pathogenesis and prognosis of
cancer. Reactive oxygen radicals formed by beta-oxidation
of branched chain fatty acids may also contribute to DNA
damage in carcinogenesis. An alternative hypothesis would
suggest that AMACR is overexpressed in the development
of cancer, perhaps playing an important role in providing
energy for the neoplastic cells. As the tumors become
dedifferentiated, they no longer require these sources of
energy.
AMACR overexpression was first proven to be an
important diagnostic marker for prostate carcinoma, but
recent studies showed that it is overexpressed in several
cancers, including colorectal carcinomas, papillary renal
cell carcinomas, hepatocellular carcinomas, melanoma,
lymphoma, and endometrium, lung, breast, bladder,
and sebaceous neoplasms (9–11,15–21). AMACR is
also overexpressed in precursor lesions like high-grade
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Table 3. AMACR expression according to clinicopathologic factors.
AMACR(+)

AMACR (-)

n

%

n

%

<60

19

63.30

21

51.20

≥60

11

36.70

20

48.80

Female

13

43.30

13

31.70

Male

17

56.70

28

68.30

Ever smoked

15

50.00

20

48.8

Nonsmokers

15

50

21

51.2

T1

3

10.00

0

0.00

T2

17

56.70

22

53.70

T3

7

23.30

10

24.40

T4

3

10.00

9

22.00

N0

26

86.70

37

90.20

N2–N3

4

13.30

4

9.80

I

2

6.70

0

0.00

II

15

50.00

20

48.80

III

8

26.70

11

26.80

IV

5

16.70

10

24.40

P-value

Median age (years)
0.439

Sex
0.45

History of smoking
1

T factor
0.146

N factor
0.714

p-Stage (pTNM)
0.445

AMACR: alpha-methylacyl-CoA racemase.

prostatic intraepithelial neoplasia and colonic adenomas
(18), but there is a limited number of studies reporting
on AMACR expression in lung cancer (9,11,13,18). Shilo
et al. reported that 47% of 477 pulmonary carcinomas
were positive for AMACR; among tumor types, 22% of
squamous cell carcinoma and 56% of adenocarcinoma were
AMACR-positive (13). Zhou et al. found that AMACR was
overexpressed in lung cancer while Jiang et al. concluded
that lung cancers were negative or rarely positive for
AMACR (11,18). The main cause of this contradiction is
the type of antibody used in these studies. In the study by
Zhou et al., a polyclonal antibody was used but Jiang et al.

used a monoclonal antibody. Nassar et al. found that only
14.3% of twenty-eight specimens with lung cancer were
positive for AMACR, where only moderate and strong
staining was considered as positive (9).
However, this is the first study about the expression
and clinical effects of AMACR in mesothelioma. In our
study, we used a monoclonal antibody and considered
weak staining as positive, which resulted in 42.3% positive
staining in all patients. However, we observed that the
expression of AMACR differs according to histological
subtypes. Epithelioid and biphasic mesothelioma had
AMACR immunoreactivity rates of 42% and 52.9%,
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Table 4. Prognostic factors in MPM.
Variables

HR

95.0% CI

Sex (male/female)

1.508

Age (>60/≤60 years)

1.426

History of smoking (ever/none)

1.793

0.550
0.639
0.616

P-value
4.130

0.425

3.186

0.386

5.215

0.284

N factor
N2–N3/N0

6.585

2.117

20.483

0.001

1.053

0.433

2.561

0.909

1.976

0.738

5.290

0.175

RT/none

0.789

0.096

6.451

0.825

CT/none

0.38

1.440

0.155

RT + CT/none

0.552

0.168

1.818

0.328

PP/none

0.843

0.163

4.366

0.839

Decortication/none

0.605

0.164

2.226

0.449

Decortication + RT and/or CT/none

0.467

0.122

1.782

0.265

2.141

0.91

5.039

0.081

Stage
Stages III–IV/Stages I–II
Histological subtypes
Epithelioid/others
Therapy modality

AMACR (–/+)

0.100

AMACR: Alpha-methylacyl-CoA racemase. MPM: malignant pleural mesothelioma.
HR: hazard ratio. CI: confidence interval. RT: radiotherapy. CT: chemotherapy.
PP: pleuropneumonectomy. None: the patients who did not receive any treatment.

respectively, whereas the patients with pure sarcomatoid
and desmoplastic mesothelioma were totally AMACRnegative. Additionally, sarcomatoid sections showed
positive staining in only five of the patients with biphasic
histology. We recommend that AMACR immunoreactivity
in the differential diagnosis of sarcomatoid and
desmoplastic mesothelioma must be further researched.
The differential diagnosis of MPM from metastatic
neoplasms of pleura, especially adenocarcinoma of lung, is
one of the most common dilemmas of thoracic pathology.
A definitive diagnosis of MPM requires a pathologic
workup including immunohistochemistry. Positive
carcinoma markers recommended for adenocarcinoma
are thyroid transcription factor 1, carcinoembryonic
antigen, LeuM1(CD15), Ber-Ep4, B72.3, HMFG-2,
MOC31, and BG8 (LewisY). There is an increasing interest
in defining positive mesothelioma markers. Positive
mesothelioma markers recommended recently include
WT-1 protein, keratin 5/6, podoplanin (D2-40), HBM1,
thrombomodulin, and calretinin (22,23).
In a previous study, which included 73 patients
with adenocarcinoma and 69 patients with squamous
cell carcinoma of the lung, the positive AMACRimmunoreactivity for each group was 59% and 42%,
respectively (14). When we compared our results with the
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results of the adenocarcinoma group in the previous study,
we found that AMACR immunoreactivity was observed
more frequently in the adenocarcinoma group than in the
MPM group (P = 0.046). The specificity and sensitivity
of AMACR immunostaining in detecting MPM were
42.3% and 41.1%, respectively. The minimum sensitivity
of an immunohistochemical marker recommended for
clinical use must be at least 80% (23). The specificity and
sensitivity of AMACR immunostaining in detecting MPM
were not sufficient enough to recommend AMACR alone
as a diagnostic tool in differential diagnosis.
The pattern of immunohistochemical staining is also
important with certain antibodies; calretinin requires both
cytoplasmic and nuclear staining to support a diagnosis
of mesothelioma, while WT-1 should be only nuclear
(23). The pattern of immunohistochemical staining for
AMACR is characterized by fine granular cytoplasmic
staining due to its localization in the peroxisome and
the mitochondrion. This pattern is easy to recognize but
in some studies about prostate carcinoma weak staining
was accepted as negative because some benign prostate
lesions show weak staining with AMACR (13). This is
logical, especially if a polyclonal antibody was used for
minimizing false positive results. However, due to studies
showing that AMACR immunoreactivity does not exist
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in alveolar parenchyma (9,11,13) and the monoclonal
antibody used in this study, we considered a weak staining
pattern to be positive.
Immunohistochemical markers also serve as
prognostic indicators. A tissue-specific effect of AMACR
immunoreactivity on degree of differentiation in colon,
breast, and bladder carcinomas was revealed by some
studies (24,25). The results of our study did not indicate any
correlations with the clinicopathologic factors including age,
sex, pathologic T status, therapy modality, or histological
subtype or stage (P > 0.05). However, in Cox regression
analysis, N status was proven to have a statistically significant
effect on overall survival of patients with MPM (P = 0.001).
This result emphasizes the prognostic significance of lymph
node involvement in the IMIG staging system for MPM. It
was found that treatment modalities used for this group of
patients did not affect the overall survival of patients. We
think this may be a good clue when it comes to researching
new therapy modalities for this challenging disease. Recent
efforts in multimodality treatment include treatment of
a symptomatic malignant pleural effusion through an
indwelling pleural catheter, systemic treatment with targeted
agents, addition of monoclonal antibodies to a standard
chemotherapy backbone, new techniques in radiation
therapy, pleural intensity-modulated radiotherapy, helical

tomography, and proton therapy (26). We may support
these efforts by encouraging our patients to participate in
these clinical trials.
In a study by Shilo et al., low-intensity staining
in small-cell carcinoma of lung in stages I and II was
associated with worse patient outcome (13). AMACR
immunoreactivity may be more intense in metabolically
active cells. Therefore, AMACR-positive groups might
show better response to chemotherapy, which may result
in better prognosis for AMACR-positive groups. Similar to
these studies, the median survival of the AMACR-positive
group in our study was better than that of the AMACRnegative group (16 and 13 months, respectively), but this
correlation could not be proven statistically through overall
survival analysis (P = 0.190). We think that the relatively
small number of patients included in this analysis and the
heterogeneity of our group in terms of performance status
and other prognostic factors might cause these statistically
nonsignificant results in survival analysis.
In conclusion, AMACR alone cannot be used
as a diagnostic tool in the differential diagnosis of
MPM, but we recommend that the effect of AMACR
expression on survival and response to chemotherapy
be further investigated in large-scale studies with a more
homogeneous study population.

References
1.

Sterman DH, Litzky LA, Albelda SM. Malignant mesothelioma
and other primary pleural tumors. In: Fishman AP, Elias
JA, Fishman JA, Grippi MA, Senior RM, Pack AI, editors.
Fishman’s Pulmonary Diseases and Disorders. 4th ed. New
York, NY, USA: McGraw-Hill; 2008. pp. 1535–1552.

8.

Zomer AW, van Der Burg B, Jansen GA, Wanders RJ, PollThe BT, van Der Saag PT. Pristanic acid and phytanic
acid: naturally occurring ligands for the nuclear receptor
peroxisome proliferator-activated receptor. J Lipid Res 2000;
41: 1801–1807.

2.

Carbone M, Kratzke RA, Testa JR. The pathogenesis of
mesothelioma. Semin Oncol 2002; 29: 2–17.

9.

3.

Huncharek M. Non-asbestos related diffuse malignant
mesothelioma. Tumori 2002; 88: 1–9.

Nassar A, Amin MB, Sexton DG, Cohen C. Utility of alphamethylacyl coenzyme A racemase (p504s antibody) as a
diagnostic immunohistochemical marker for cancer. Appl
Immunohistochem Mol Morphol 2005; 13: 252–255.

4.

Gabrielson EW, Pinn ML, Testa JR, Kuhajda FP. Increased fatty
acid synthase is a therapeutic target in mesothelioma. Clin
Cancer Res 2001; 7: 153–157.

10.

5.

Niu K, Asada M, Okazaki T, Yamanda S, Ebihara T, Guo H,
Zhang D, Nagatomi R, Arai H, Kohzuki M et al. Adiponectin
pathway attenuates malignant mesothelioma cell growth. Am J
Respir Cell Mol Biol 2012; 46: 515–523.

Luo J, Zha S, Gage WR, Dunn TA, Hicks JL, Bennett CJ,
Ewing CM, Platz EA, Ferdinandusse S, Wanders RJ et al.
Alpha-methylacyl-CoA racemase: a new molecular marker for
prostate cancer. Cancer Research 2002; 62: 2220–2226.

11.

6.

Cardillo I, Spugnini EP, Verdina A, Galati R, Citro G, Baldi A.
Cox and mesothelioma: an overview. Histol Histopathol 2005;
20: 1267–1274.

Jiang Z, Fanger GR, Woda BA, Banner BF, Algate P, Dresser K,
Xu J, Chu PG. Expression of alpha-methylacyl-CoA racemase
(P504s) in various malignant neoplasms and normal tissues: a
study of 761 cases. Hum Pathol 2003; 34: 792–796.

12.

7.

Ferdinandusse S, Denis S, IJlst L, Dacremont G, Waterham HR,
Wanders RJA. Subcellular localization and physiological role of
a-methylacyl-CoA racemase. J. Lipid Res 2000; 41: 1890–1896.

Rusch VW. A proposed new international TNM staging system
for malignant pleural mesothelioma. From the International
Mesothelioma Interest Group. Chest 1995; 108: 1122–1128.

13.

Shilo K, Dracheva T, Mani H, Fukuoka J, Sesterhenn IA, Chu
WS, Shih JH, Jen J, Travis WD, Franks TJ. Alpha-methylacyl
CoA racemase in pulmonary adenocarcinoma, squamous
cell carcinoma, and neuroendocrine tumors: expression and
survival analysis. Arch Pathol Lab Med 2007; 131: 1555–1560.

613

DUYAR et al. / Turk J Med Sci
14.

Erdogan Y, Demirag F, Duyar SS, Yilmaz A, Yazıcı Ü, Aydoğdu
K. The expression and clinical effects of alpha-methylacyl-CoA
racemase (AMACR/ P504S) in squamous cell carcinoma and
adenocarcinoma of lung. Acta Chir Belg 2011; 113: 263–269.

15.

Li MY, Yuan H, Ma LT, Kong AW, Hsin MK, Yip JH, Underwood
MJ, Chen GG. Roles of PPAR{alpha} and PPAR {gamma} in the
development of non-small cell lung cancer. Am J Respir Cell
Mol Biol 2010; doi:10.1165/rcmb.2009-0349OC.

16.

Xu J, Stolk JA, Zhang X, Silva SJ, Houghton RL, Matsumura M,
Vedvick TS, Leslie KB, Badaro R, Reed SG. Identification of
differentially expressed genes in human prostate cancer using
subtraction and microarray. Cancer Res 2000; 60: 1677–1682.

17.

Daugherty SE, Platz EA, Shugart YY, Fallin MD, Isaacs WB,
Chatterjee N, Welch R, Huang WY, Hayes RB. Variants in the
alpha-methylacyl-CoA racemase gene and the association
with advanced distal colorectal adenoma. Cancer Epidemiol
Biomarkers Prev 2007; 16: 1536–1542.

18.

Zhou M, Chinnaiyan AM, Kleer CG, Lucas PC, Rubin MA.
Alpha-methylacyl-CoA racemase: a novel tumor marker
overexpressed in several human cancers and their precursor
lesions. Am J Surg Pathol 2002; 26: 926–931.

19.

Tretiakova MS, Sahoo S, Takahashi M, Turkyilmaz M,
Vogelzang NJ, Lin F, Krausz T, Teh BT, Yang XJ. Expression
of alpha-methylacyl-CoA racemase in papillary renal cell
carcinoma. Am J Surg Pathol 2004; 28: 69–76.

20.

Went PT, Sauter G, Oberholzer M, Bubendorf L. Abundant
expression of AMACR in many distinct tumour types.
Pathology 2006; 38: 426–432.

614

21.

Halsey MA, Calder KB, Mathew R, Schlauder S, Morgan MB.
Expression of alpha-methylacyl-CoA racemase (P504S) in
sebaceous neoplasms. J Cutan Pathol 2010; 37: 446–451.

22.

Comin CE, Novelli L, Boddi V, Paglierani M, Dini S. Calretinin,
thrombomodulin, CEA, and CD15: a useful combination
of immunohistochemical markers for differentiating
mesothelioma from pulmonary adenocarcinoma. Hum Pathol
2001; 32: 529–532.

23.

Husain AN, Colby T, Ordonez N, Krausz T, Attanoos R,
Beasley MB, Borczuk AC, Butnor K, Cagle PT, Chirieac
LR et al. Guidelines for pathologic diagnosis of malignant
mesothelioma: a consensus statement from the International
Mesothelioma Interest Group. Arch Pathol Lab Med 2009; 133:
1317–1331.

24.

Witkiewicz AK, Varambally S, Shen R, Mehra R, Sabel MS,
Ghosh D, Chinnaiyan AM, Rubin MA, Kleer CG. Alphamethylacyl-CoA racemase protein expression is associated
with the degree of differentiation in breast cancer using
quantitative image analysis. Cancer Epidemiol Biomarkers
Prev 2005; 14: 1418–1423.

25.

Kuefer R, Varambally S, Zhou M, Lucas PC, Loeffler M, Wolter
H, Mattfeldt T, Hautmann RE, Gschwend JE, Barrette TR et
al. α-Methylacyl-CoA racemase: expression levels of this novel
cancer biomarker depend on tumor differentiation. Am J
Pathol 2002; 161: 841–848.

26.

Hiddinga BI, Surmont VF, Van Meerbeeck JP. Management of
malignant pleural mesothelioma: have we made any progress?
Panminerva Med 2013; 55: 157–173.

